A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 93.40
GOOG 675.22
MSFT 49.83
FB 112.08
BAC 13.00

Recently Added

WNC 12.53
SUNEQ 0.13
CIX 10.97
ZBH 116.69
SPHS 1.86

Gaining Speed

SUNEQ 0.13
WNC 12.53
EXAS 11.54
STE 65.44
VG 5.68

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!